GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Smruthi Organics Ltd (BOM:540686) » Definitions » Valuation Rank

Smruthi Organics (BOM:540686) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is Smruthi Organics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Smruthi Organics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Smruthi Organics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Smruthi Organics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Smruthi Organics Ltd (BOM:540686) » Definitions » Valuation Rank
Comparable Companies
NSE:MADHAVBAUG NSE:ZENITHDRUG BOM:540702 BOM:524652 BOM:524412 NSE:SOTAC BOM:530233 BOM:538964 BOM:531592 NSE:JFLLIFE ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
N/A
Address
165-A, Balaji Bhavan, 1st Floor, Railway Lines, Solapur, MH, IND, 413 001
Website
https://www.smruthiorganics.com
Smruthi Organics Ltd is engaged in the manufacture of bulk drugs and drug intermediates (API Products). The product portfolio includes Amlodipine Besilate, Amlodipine Base, S-Amlodipine Besilate, S-Amlodipine Base, Norfloxacin, Metformin HCI, Diloxanide Furoate, Phthaloyl Amlodipine, Pantoprazole Sodium, Pefloxacin Mesylate Dihydrate, Telmisartan, Losartan Potassium and many more. It has two segments Bulk Drugs and Drugs Intermediates (API) and Formulation. It generates the majority of its revenue from the Bulk Drugs and Drugs Intermediates (API) segment.